Knowing that alterations in the PI3K/Akt pathway are so common and important in cancer, multiple antagonists have been developed throughout the years in the hopes of providing better and more efficient therapeutic strategies to cancer patients, especially as so many of them harbor upregulation of this pathway and often develop resistance to standard treatment [38]. The gene discussed is PIK3CB; the disease is cancer.